MFN Pricing: Mitigation Strategies for Pharma Companies in 2026
Most Favoured Nation (MFN) pricing policies are increasingly shaping global pharmaceutical launch, pricing, and access strategies. As MFN concepts link
GENEROUS Changes Everything: How the New CMS MFN Model Is Reshaping U.S. Drug Pricing in 2025–2026
What began as “Most Favored Nation” (MFN) concepts has now materialized into concrete policy mechanisms. From binding bilateral MFN agreements
2025: Looking Back After Almost One Year of the EU JCA
The EU Health Technology Assessment Regulation (HTAR) represents one of the most significant shifts in the European health-innovation landscape in
2025 U.S. Pharma Industry and Market Access Key Facts
In 2023, U.S. retail prescription drug market value grew 11.4% to $449.7B, about 9% of total health care outlays1. “Retail
AIFA 2025 Annual Report: Key Insights into Italian Market Access, Pricing, and Pharma and Biotech Innovation
The Italian Medicines Agency has published their annual AIFA Activity Report in 2025, outlining the key facts and figures regarding
Tariffs: Should Pharma and Biotech Manufacturers Relocate / Build Manufacturing in the U.S.?
As U.S. trade policy tightens, pharmaceutical and biotech companies face a pivotal strategic question: does it now make financial sense